Genetic Mutations
359 articles
Having a genetic mutation can make all the difference in treatment choices, and even longer-term survival. Learn more about the importance of genetic testing and molecular profiling.
Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligible to try a new drug.
Understanding Family History Makes a Difference in Treatment Options
Elizabeth Pršić describes her mother Andrea’s pancreatic cancer treatment. Andrea has the BRCA2 mutation, which helps determine the plan.
What Caused My Pancreatic Cancer?
Despite no known genetic link, Steven Robinson is the fourth member of his family on his mother’s side to get pancreatic cancer.
RNA Precision Trial for Pancreatic Cancer Opens At Columbia
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
The Value of Molecular Profiling and Genetic Testing
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random.
Testing Vitamin C as a Cancer Killer
Lewis Cantley’s team is starting clinical trials of vitamin C to gain more information about its role in stopping cancer.
AACR Virtual Special Conference on Pancreatic Cancer: Day Two Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day Two of the AACR Virtual Special Conference on Pancreatic Cancer.
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
No One Fights Alone
Because of her grandfather, Rhonda Havig knew she had a family history of pancreatic cancer. But her own diagnosis was still a surprise.
Study Reveals Molecular Differences in Young-Onset Pancreatic Cancer
There has been a notable increase in cases of young onset pancreatic cancer. Dr. Jashodeep Datta and team are exploring why this is happening.
Tumor Biology Matters
Dr. Lynn Matrisian of PanCAN, explains that molecular profiling of a pancreatic cancer patient’s tumor can show which treatment will work best.
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.